DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Scott Schoenhaus - 1 Chris Gibson - 1 Jensen Huang - 1 Leerink - 1 Mani Foroohar - 1 Foroohar - 1 Recursion's - 1 KeyBanc's Schoenhaus - 1
Top related locs:
U.S biopharma Biohive Japan United States
Top related orgs:
Therapeutics - 2 Analysts - 1 Capital - 1 Nvidia - 1 ARK Investment Management - 1 REC - 1 CCM - 1 Union - 1

Search resuls for: "Japan's Takeda"


2 mentions found


☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
  + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
☆ Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
  + stars: | 2023-07-27 | by ( ) www.reuters.com   time to read: +2 min
Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said. That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv. The company held its forecast for full-year operating profit at 349 billion yen. Analysts expect 481.1 billion yen on average for the year.
Persons: Takeda, Rocky Swift, Tom Hogue, Robert Birsel Organizations: Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson Locations: Japan, United States, U.S
0 next >>
Total: 2